https://revistaschilenas.uchile.cl/handle/2250/36725 2026-05-06T09:17:37Z https://revistaschilenas.uchile.cl/handle/2250/111580 SÍNDROME DE TAKO-TSUBO: CASO CLÍNICO El síndrome de Tako-Tsubo es una entidad clínica poco frecuente que imita a un infarto agudo del miocardio, en cuanto a sintomatología, parámetros de laboratorio y cambios electrocardiográficos. Sin embargo, a la angiografía no presenta evidencia de oclusión coronaria  y  se observa de manera característica balonamiento apical del ventrículo izquierdo en sístole. Su etiopatogenia se asocia a trastorno simpático, aunque existen controversias al respecto. Reportamos un caso de una mujer de 78 años, sin factores de riesgo coronario, admitida en el servicio de urgencia por dolor precordial y electrocardiograma concordante con síndrome coronario agudo con supradesnivel del ST. Los marcadores de daño miocárdico fueron positivos (troponinas, CK-total y CK-MB). Se realizó angiografía de urgencia que no evidenció oclusión coronaria y por el balonamiento apical a la ventriculografía izquierda se planteó como probable el diagnóstico de síndrome de Tako-Tsubo. La paciente tuvo una evolución favorable y el seguimiento al mes con test de esfuerzo, ecocardiograma y SPECT de perfusión miocárdica resultaron sin evidencias de isquemia y con función sistólica del ventrículo izquierdo conservada.      https://revistaschilenas.uchile.cl/handle/2250/111579 DIRECT ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION. EXPERIENCE IN 106 PATIENTS; Nuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC). Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p; Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p https://revistaschilenas.uchile.cl/handle/2250/111578 Gastropatía hipertrófica por IgG4. Reporte del primer caso en Chile.; IgG4 RELATED HYPERTROPHIC GASTROPATHY. REPORT OF ONE CASE IgG4 related disease is a systemic autoimmune disease, which can affect different organs. The most common digestive manifestation is autoimmune pancreatitis (AIP), followed by involvement of bile ducts and the major papilla. The stomach is only rarely involved. We report a 71 years old diabetic woman consulting for jaundice and weight loss. Abdominal CAT scan, cholangio resonance imaging, endosonography and a serum IgG4 of five times the normal value, lead to the diagnosis of an autoimmune pancreatitis. An upper gastrointestinal endoscopy showed a diffuse thickening of gastric folds. The pathological study confirmed the presence of IgG4 positive plasma cells. The patient was successfully treated with steroids.; IgG4 related disease is a systemic autoimmune disease, which can affect different organs. The most common digestive manifestation is autoimmune pancreatitis (AIP), followed by involvement of bile ducts and the major papilla. The stomach is only rarely involved. We report a 71 years old diabetic woman consulting for jaundice and weight loss. Abdominal CAT scan, cholangio resonance imaging, endosonography and a serum IgG4 of five times the normal value, lead to the diagnosis of an autoimmune pancreatitis. An upper gastrointestinal endoscopy showed a diffuse thickening of gastric folds. The pathological study confirmed the presence of IgG4 positive plasma cells. The patient was successfully treated with steroids. https://revistaschilenas.uchile.cl/handle/2250/111567 VALIDATION OF THE EAT-10 SCORE TO DETECT DYSPHAGIA IN OLDER PEOPLE; Validez y confiabilidad del cuestionario Eating Assessment Tool 10 (EAT-10) para detectar disfagia en adultos mayores chilenos. Background: In Chile, comprehensive geriatric assessment does not include the identification of dysphagia, despite being considered a geriatric syndrome. The Eating Assessment Tool 10 (EAT-10) questionnaire is a 10-question instrument that specifically describes the perception of dysphagia and has a Spanish translation. Aim: To validate and test the reliability of the EAT-10 questionnaire in Chilean older people living in the community. Material and methods: the EAT- 10 score was applied to 80 participants aged 75 ± 14 years (51 women). Other observer, blinded to the result of the score, performed the volume-viscosity swallow test as the gold standard to assess dysphagia. Results: The translated version of the EAT-10 had a strong internal consistency (Cronbach alfa =0.89) and interobserver consistency (100%). Using a score of seven as cutoff point, the EAT-10 had a sensitivity of 75%, specificity of 86% to detect dysphagia, when compared with the volume-viscosity swallow test. Conclusions: The EAT-10 questionnaire is valid and reliable and can be used as a clinical instrument in primary care in our country to identify older people with dysphagia.; Background: In Chile, comprehensive geriatric assessment does not include the identification of dysphagia, despite being considered a geriatric syndrome. The Eating Assessment Tool 10 (EAT-10) questionnaire is a 10-question instrument that specifically describes the perception of dysphagia and has a Spanish translation. Aim: To validate and test the reliability of the EAT-10 questionnaire in Chilean older people living in the community. Material and methods: the EAT- 10 score was applied to 80 participants aged 75 ± 14 years (51 women). Other observer, blinded to the result of the score, performed the volume-viscosity swallow test as the gold standard to assess dysphagia. Results: The translated version of the EAT-10 had a strong internal consistency (Cronbach alfa =0.89) and interobserver consistency (100%). Using a score of seven as cutoff point, the EAT-10 had a sensitivity of 75%, specificity of 86% to detect dysphagia, when compared with the volume-viscosity swallow test. Conclusions: The EAT-10 questionnaire is valid and reliable and can be used as a clinical instrument in primary care in our country to identify older people with dysphagia.